PsychedelicNewsBreaks

FridayAug 21, 2020 1:43 pm

PsychedelicNewsBreaks – Pure Extracts Corp. Holds Clear Advantage in Space Where Purity, Quality Are Equal

Pure Extracts, a private, plant-based extraction company, stands out to meet demand in the psychedelic and functional mushroom industries, which are among North America’s fastest-growing segments.  While few can deliver to this emerging space that requires extraction for product development, Pure Extracts leverages substantial experience and technical competence, creating a distinct advantage as it focuses on partnering with companies developing powerful mushroom products. A recent article discussing this reads, “With its proven expertise and EU Good Manufacturing Practices (“GMP”) designed facility for licensed extraction, Pure Extracts offers a clear competitive advantage. In a space where product purity is equal to…

Continue Reading

WednesdayAug 19, 2020 2:03 pm

PsychedelicNewsBreaks – Cybin Corp. Partners with IntelGenx to Develop Efficient Delivery Method for Pharmaceutical-Grade Psilocybin

Cybin Corp. recently announced its entry into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://ibn.fm/TZeVy). Under the agreement, the two companies will collaborate to develop an orally dissolving, fast-acting film for the delivery of pharmaceutical-grade psilocybin. A recent article discussing this quotes Cybin’s Chief Medical Officer Dr. Jukka Karjalainen, who states, “We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film. Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic…

Continue Reading

FridayAug 07, 2020 5:58 pm

PsychedelicNewsBreaks — Cybin Calls Approval for Psilocybin Therapy in Palliative Care Treatment a ‘Watershed Moment’

Cybin Corp., Canada's leading-edge mushroom life-sciences company, has noted its strong support for TheraPsil, a nonprofit coalition that advocates for legal, Special Access Programme ("SAP") access to psilocybin therapy for palliative care of Canadians. The coalition recently announced that Federal Minister of Health Patty Hajdu has approved the use psilocybin therapy in the end-of-life care for four Canadians diagnosed with incurable cancer. The four are the first publicly known individuals to legally use psilocybin since the compound became illegal in Canada in 1974. “This is a watershed moment for the patients involved who deserve the right to manage their health…

Continue Reading

WednesdayAug 05, 2020 11:24 am

PsychedelicNewsBreaks – Cybin Corp. Positioned in Shifting Trend Toward Psilocybin

Cybin Corp., Canada's premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products, looks to be at the right place at the right time during a shifting trend toward psilocybin. Highlighting this shift, TheraPsil, a non-profit coalition that advocates for legal, compassionate access to psilocybin therapy for palliative Canadians, recently shared news that four palliative Canadians were approved for end-of-life psilocybin therapy. This approval, through section 56(1), represents the first legal medical exemptions for psilocybin in Canada since the 1970s. “I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgement…

Continue Reading

TuesdayAug 04, 2020 12:39 pm

PsychedelicNewsBreaks – Pure Extracts Corp. to Drive Product Innovation with Leading-Edge Team, Technology

Pure Extracts, a private, plant-based extraction company with a new vertical in functional mushrooms, leverages a team of qualified experts and cutting-edge technology. The company’s distinction on a path toward opportunity was highlighted in a recent article, which reads, “Pure Extracts, on the other hand, is ideally positioned to enter the space as an experienced producer. With a team of qualified experts and cutting-edge extraction technology, the company is set up for long-term strategic distribution and product innovation. Located near Whistler, British Columbia, the company’s facility is built for EU-GMP certification, which allows for international sales and ensures the production…

Continue Reading

WednesdayJul 29, 2020 2:06 pm

PsychedelicNewsBreaks – Cybin Corp. to Deliver Psychedelic Medicines Targeting Conditions Failed by Big Pharma

Cybin Corp. appears set for opportunity as new data increasingly finds promise in psychedelic medicines. As big pharma has failed to bring groundbreaking drug innovations into the mental-health space, psilocybin — the main compound of pharmaceutical psychedelic products — stands out, having shown positive results for the treatment of anxiety, depression, addiction, and eating and other disorders. A recent article discussing the company’s positioning reads, “Cybin is potentially poised to be the first company to develop psilocybin-based medicine designed to target major depressive disorders. Currently involved in structuring a clinical study that will be conducted through an academic partner in…

Continue Reading

MondayJul 27, 2020 9:38 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Files Acquisition Reports, Appoints New Director

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), on Friday announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. The filings are part of Champignon’s commitment to work with the British Columbia Securities Commission to complete its previously announced disclosure review. The Company also announced its appointment of Dr. Roger McIntyre, Champignon CEO, to its Board of Directors. Dr. McIntyre’s appointment will replace Pat McCutcheon’s position as a director of the Company. To view the full press release, visit http://ibn.fm/RDypi About Champignon Brands Inc.…

Continue Reading

WednesdayJul 22, 2020 1:05 pm

PsychedelicNewsBreaks – Pure Extracts Corp. Leverages CO2 Technology in ‘Extraction Is Our Business’ Model

Pure Extracts, a private, plant-based extraction company with a new vertical in functional mushrooms, leverages CO2 technology, a process based on pressurized carbon dioxide that provides some of today’s cleanest, healthiest products. The company’s dedication to this process was highlighted in a recent article, which reads, “Pure Extract’s Vitalis C02 extraction technology allows for full-spectrum oil extraction, which results in the purest, highest-quality oil. In addition, the company, which notes that ‘extraction is our business,’ will soon have the capacity for more than 100,000 kg of biomass per year with a technique that has been tried and tested through its…

Continue Reading

WednesdayJul 22, 2020 12:52 pm

PsychedelicNewsBreaks – Cybin Corp. Advancing ‘Fungi-Derived’ Products Amid Mushrooming Interest in Psychedelics

Cybin Corp., a Canada-based, life-sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, looks to be in the right place at the right time. A mushrooming interest fuels this sector in an era where psychedelics, once a taboo substance, are being viewed in a powerful new light. A recent article discussing the company and its focus in this emerging space reads, “Cybin is committed to its mission of bringing ‘fungi-derived psychedelic and medicinal products into the world that may potentially drive the next discovery phase of life-changing medications to treat mental illness…

Continue Reading

TuesdayJul 14, 2020 1:39 pm

PsychedelicNewsBreaks – Pure Extracts Corp. Moves to Further Expand in the Functional Mushrooms Market

Pure Extracts, a private, plant-based extraction company, is focused on becoming a dominant extraction company in the functional mushrooms market, as well as a leader in the rapid development and commercialization of products in the emerging sector. A recent article discussing this reads, “Further establishing its power in the market, Pure Extracts has signed nondisclosure agreements to explore joint-development endeavors for product launches slated for potential Q4 delivery. The company also inked an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc., the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health…

Continue Reading